Radiation and oncology immunotherapy specialist Cleveland BioLabs (NASDAQ:CBLI) and Roswell Park Cancer Institute highlighted data has been released which shows its entolimod protein suppresses metastasis
The data was published in the official journal of the United States National Academy of Sciences, based on studies conducted by scientists at RPCI and Cleveland BioLabs.
Entolimod is a protein which is currently being developed for dual purposes – as a radiation countermeasure and as a cancer treatment.
It supresses metastasis, which, in this case, is the spread of a cancer from one organ or part to another not directly connected with it.
Entolimod induces chemokines that attract NK cells to the liver, which then work as an “antitumor”.
Importantly, antitumor effects in the liver combine with responses in the body to supress the spread of the disease to the lung.
The liver is a common site of cancer metastases for many cancers, including cancers of the gastrointestinal tract.
Andrei Gudkov, chief scientific officer of Cleveland BioLabs, said: "These observations have elucidated the mechanisms of entolimod's immunotherapeutic activity”.
“This work suggests that entolimod enables vaccination against tumor cells residing in the liver through a mechanism that does not require identification of a particular tumor antigen."